Clinical trials: Human Immunodeficiency Virus Type 1
HIV, Cancer
Durvalumab in HIV-1 Patients With Solid Tumors
The proposal is a phase II clinical study designed to assess the feasibility of durvalumab (MEDI4736) in HIV-1-infected individuals with solid tumors.
- Trial name
- NCT03094286
- Testing
- Durvalumab
- Where
- 8 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Spanish Lung Cancer Group
HIV Infections
Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults
The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-Naïve (TN) participants.
- Trial name
- CINNAMON (NCT06039579)
- Testing
- VH4004280, VH4011499, Antiretroviral therapy
- Where
- 20 sites in United States, Argentina and 7 more
- Volunteers
- 44 people
- Sponsor
- ViiV Healthcare
HIV-1 Infections
Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
The objective of this study is to monitor Health Outcomes of Interest (HOI) in participants with human immunodeficiency virus-1 (HIV-1) infection following treatment with Raltegravir.
- Trial name
- NCT01078246
- Volunteers
- 7,124 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
The purpose of this study is to assess the safety of GX-12 gene therapy combined with HAART in the HIV-1 infected patients and to investigate the efficacy with the value of plasma viral load and with CD4 counts and HIV-1 specific…
- Trial name
- NCT00517569
- Testing
- GX-12, HAART
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Genexine, Inc.
HIV-1 Infection
The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
The purpose of this study is to compare HIV RNA expression and infection within resting (CD4)+ cells in HIV-infected patients on stable ART before and after a single exposure to Vorinostat (VOR), after exposure to short intervals…
- Trial name
- NCT01319383
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of North Carolina, Chapel Hill
People Living With HIV, Antibody Response
RENEW-SHCS: Safety and Immunogenicity of a Recombinant HIV Env Protein Vaccine in ARV-treated Adults Living With HIV in the SHCS
A vaccine trial in which people with HIV-1 participating in the Swiss HIV Cohort Study will receive a HIV-specific vaccine to stimulate antibodies against HIV while continuing their standard antiretroviral therapy
- Trial name
- RENEW-SHCS (NCT07769983)
- Testing
- The Patients will all receive a vaccination with a recombinant HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 vaccine, adjuvanted,.
- Where
- 2 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Zurich
HIV Infections, Hepatitis C
A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection
This study evaluates patients infected with both HIV and Hepatitis C virus (HCV) who are receiving anti-HIV drugs. The purpose of this study is to learn more about HCV infection in patients whose HIV blood level decreases to less…
- Trial name
- NCT00001117
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels
Master Protocol: The main goal of this master clinical study is to evaluate the safety, tolerability, efficacy, and pharmacokinetic (PK) of long-acting oral (LAO) regimens in people with HIV-1 (PWH).
- Trial name
- NCT07841990
- Testing
- B/F/TAF, GS-3242, Lenacapavir
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Gilead Sciences
HIV Infections, Helminthiasis
Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation
Identifying methods to slow disease progression in patients with HIV-1 infection remains a top priority in many regions of the world.
- Trial name
- NCT00130910
- Testing
- Albendazole
- Where
- Kenya
- Volunteers
- 234 people
- Sponsor
- University of Washington
HIV-1 Infection
Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients
A pilot study to compare the efficacy and safety of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection.
- Trial name
- NCT01989910
- Testing
- Raltegravir, Efavirenz
- Where
- Taiwan
- Volunteers
- 107 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
HIV Infections
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
This study will evaluate the safety, pharmacokinetics and efficacy of the CCR5 antagonist INCB009471 in HIV-1 infected patients who are antiretroviral therapy naïve, or who are not currently on a HAART regimen and have not…
- Trial name
- NCT00393120
- Testing
- INCB009471
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- Incyte Corporation
HIV-1 Infection
Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients
The purpose of this study is to assess the impact of allogeneic hematopoietic stem cell transplantations (HSCT) in HIV infected patients on the persistence of HIV and the HIV immune response.
- Trial name
- HSCT-HIV (NCT02732457)
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- Kirby Institute
Human Immunodeficiency Virus Type 1 (HIV-1)
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
The purpose of the study is to compare the pharmacokinetics and bioequivalence of atazanavir in a fixed-dose combination with cobicistat with that of atazanavir coadministered with cobicistat as single agents.
- Trial name
- Atazanavir (NCT01837719)
- Testing
- Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV-1-infection, ART
Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia
This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid tissue of HIV-infected individuals receiving…
- Conditions
- HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection
- Trial name
- NCT05700630
- Testing
- FT538, Vorinostat
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
HIV Infections
A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children
Monotherapy phase: To evaluate and compare the safety, tolerance, pharmacokinetics, and preliminary activity of nevirapine administered alone in mildly to moderately symptomatic HIV-infected children ages 2 months to less than 18…
- Trial name
- NCT00001111
- Testing
- Nevirapine, Zidovudine
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
The study examines the safety and effectiveness of ritonavir (an anti-HIV drug), alone and in combination with other anti-HIV drugs, in HIV-positive children under 2 years of age.
- Trial name
- NCT00000952
- Testing
- Ritonavir, Lamivudine, Zidovudine
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infections
Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
The primary objectives of this study are to evaluate the steady-state pharmacokinetics (PK) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) single-tablet regimen…
- Trial name
- NCT01721109
- Testing
- EVG/COBI/FTC/TDF
- Where
- 18 sites in United States, South Africa and 1 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
HIV Infections
Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications
The purpose of this study is to evaluate the safety of two HIV vaccines in HIV-1-infected young adults who are taking anti-HIV medications and have very low virus levels.
- Trial name
- NCT01909414
- Testing
- GEO-D03 DNA Vaccine, MVA/HIV62B Vaccine
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus-type 1 Infection
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
The purpose of this study is to demonstrate noninferiority (a new treatment is equivalent to standard treatment) in terms of the percentage of patients who have plasma human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid…
- Trial name
- SALIF (NCT01709084)
- Testing
- Rilpivirine, Efavirenz, Tenofovir disoproxil fumarate
- Where
- 18 sites in Cameroon, Kenya and 4 more
- Volunteers
- 426 people
- Sponsor
- Janssen-Cilag International NV
HIV-1-infection
A Study to Test Three Experimental HIV Vaccines in Healthy Adults.
HIV-CORE 006 is a Phase 1 double-blind placebo-controlled trial, in which the mosaic immunogens are delivered by a prime-boost regimen of non-replicating simian adenovirus followed by non-replicating poxvirus MVA.
- Trial name
- HIV-CORE 006 (NCT04553016)
- Testing
- Vaccine
- Where
- 4 sites in Kenya, Uganda and 1 more
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Oxford
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.